The effects of blood glucose management on 90-day all-cause mortality intensive care unit (ICU) patients

ISRCTN ISRCTN04968275
DOI https://doi.org/10.1186/ISRCTN04968275
ClinicalTrials.gov number NCT00220987
Secondary identifying numbers 293201; SUGAR NCT00175331; NICE NCT00220987
Submission date
26/08/2004
Registration date
25/10/2004
Last edited
18/08/2010
Recruitment status
No longer recruiting
Overall study status
Completed
Condition category
Nutritional, Metabolic, Endocrine
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data

Plain English summary of protocol

Not provided at time of registration

Study website

Contact information

Prof Simon Finfer
Scientific

Intensive Care Unit
Royal North Shore Hospital
Pacific Highway
St. Leonard's
Sydney
2065
Australia

Phone +61 (0)2 9926 8656
Email sfinfer@med.usyd.edu.au

Study information

Study designRandomised, parallel, two armed trial, with outcome assessor and data analyst blinding
Primary study designInterventional
Secondary study designRandomised controlled trial
Study setting(s)Hospital
Study typeTreatment
Scientific titleA multi-centre, open label randomised stratified controlled trial of the effects of blood glucose management on 90-day all-cause mortality in a heterogeneous population of intensive care unit (ICU) patients
Study acronymNICE-SUGAR STUDY
Study objectivesThe hypothesis is that there is no difference in the relative risk of death between patients assigned a glucose range of 4.5 - 6.0 mmol/l and those assigned a glucose range of less than 10.0 mmol/l with insulin being infused if blood glucose exceeds 10.0 mmol/l, and adjusted when needed to maintain blood glucose of 8.0 - 10.0 mmol/l.

Acronym meaning: Normoglycaemia in Intensive Care Evaluation and Survival Using Glucose Algorithm Regulation
Ethics approval(s)Canadian main site: Clinical Research Ethics Board of the University of British Columbia, Vancouver approved on 21st March 2006
Health condition(s) or problem(s) studiedHyperglycaemia in critically ill patients
InterventionThe total projected recruitment for this trial is 6000 patients: 4000 in Australia and New Zealand (between April 2005 and December 2006) and 2000 in Canada (between May 2006 and September 2009). The Canadian leg of the trial will start on 01/05/2006 and is anticipated to run until the 30/09/2009.

Interventions for all participating centres:
Each participant will be randomised to receive an insulin sliding scale regimen to control blood glucose concentration between 4.5 - 6.0 mmol/l or insulin infused if blood glucose exceeds 10.0 mmol/l, and adjusted when needed to maintain blood glucose between 8.0 - 10.0 mmol/l

The trial sponsors for the Canadian leg of trial are:
1. The University of British Columbia
2329 West Mall
Vancouver
BC Canada
V6T 1Z4
2. Vancouver Coastal Health Research Institute
828 West 10th Avenue
Vancouver
BC, Canada
V5Z 1L8
3. George Institute for International Health

For further information on Canadian arm of trial, please contact the following:
1. Dr Vinay Dhingra at vinay.dhingra@vch.ca
2. Denise Foster, RN, CRC at Denise.Foster@vch.ca
Intervention typeDrug
Pharmaceutical study type(s)
PhaseNot Applicable
Drug / device / biological / vaccine name(s)Glucose, insulin
Primary outcome measure90 day all-cause mortality
Secondary outcome measuresDetermined over the same period (90 days):
1. Death in intensive care unit by day 28 and by 90 days
2. Length of intensive care unit stay
3. Length of hospital stay
4. The need for organ support (intropes, renal replacement therapy and positive pressure ventilation)
5. Incidence of blood stream infections
6. Incidence and severity of hypoglycaemia

Also in a subgroup of patients admitted with a diagnosis of traumatic brain injury, a follow up to determine long term functional status as determined by Extended Glasgow Outcome Scores (GOSE) will be collected at day 90 and six months.
Overall study start date04/04/2005
Completion date30/09/2009

Eligibility

Participant type(s)Patient
Age groupAdult
Lower age limit18 Years
SexBoth
Target number of participants6000 (2207 patients recruited as of 4/08/06)
Key inclusion criteria1. Patients (18 years or over, either sex) that are expected to require treatment in the ICU that extends beyond the calendar day following the day of admission
2. Patient has an arterial line in place or placement of an arterial line is imminent (within the next hour) as part of routine ICU management
Key exclusion criteriaPatients are excluded from the study if ONE or MORE of the following criteria are present:
1. Age less than 18 years
2. Imminent death and the treating clinicians are not committed to full supportive care
3. Patients admitted to the ICU for treatment of diabetic ketoacidosis or hyperosmolar state
4. Patients that are expected to be eating before the end of the day following admission
5. Patients who have suffered hypoglycaemia without documented full neurological recovery
6. Patients thought to be at abnormally high risk of suffering hypoglycaemia
7. If a patient has previously been enrolled in the study
8. If the patient cannot provide prior informed consent, there is documented evidence that the patient has no legal surrogate decision maker and it appears unlikely that the patient will regain consciousness or sufficient ability to provide delayed informed consent
9. The patient has been in the study ICU or another ICU for longer than 24 hours for this admission
Date of first enrolment04/04/2005
Date of final enrolment30/09/2009

Locations

Countries of recruitment

  • Australia
  • Canada
  • New Zealand

Study participating centre

Intensive Care Unit
Sydney
2065
Australia

Sponsor information

Australian and New Zealand Intensive Care Society (Australia)
Research organisation

Level 3, 10 Levers Terrace
Carlton
Victoria
3053
Australia

Website http://www.anzics.com.au/ctg/about.htm
ROR logo "ROR" https://ror.org/007847151

Funders

Funder type

Research council

Australian National Health and Medical Research Council (NHMRC) (Australia) (ref: 293201)

No information available

New Zealand Health Research Council (New Zealand) (ref: 05/078)

No information available

Canadian Institutes of Health Research (CIHR) (Canada) - www.cihr-irsc.gc.ca (ref: MCT-80244)

No information available

Results and Publications

Intention to publish date
Individual participant data (IPD) Intention to shareNo
IPD sharing plan summaryNot provided at time of registration
Publication and dissemination planNot provided at time of registration
IPD sharing plan

Study outputs

Output type Details Date created Date added Peer reviewed? Patient-facing?
Results article results 26/03/2009 Yes No